Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William S M Wold

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Advances in Cancer Research|October 2, 2012
Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compoundsWilliam S M Wold, Karoly Toth
Current Gene Therapy|November 28, 2013
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyWilliam S M Wold, Karoly Toth
Virology|September 3, 2003
Adenovirus ADP protein (E3-11.6K), which is required for efficient cell lysis and virus release, interacts with human MAD2BBaoling Ying, William S M Wold
Viruses|October 14, 2011
Increasing the efficacy of oncolytic adenovirus vectorsKaroly Toth, William S M Wold
Expert Opinion on Pharmacotherapy|September 3, 2015
New drug on the horizon for treating adenovirusWilliam S M Wold, Karoly Toth
Virus Research|October 27, 2009
Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosisVera L Tarakanova, William S M Wold
Journal of Virology|August 14, 2003
Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cellsVera L Tarakanova, William S M Wold
Cancer Gene Therapy|September 11, 2004
Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmissionDrew L Lichtenstein, William S M Wold
Methods in Molecular Biology (Clifton, N.J.)|September 28, 2011
Syrian hamster tumor model to study oncolytic Ad5-based vectorsDebanjan Dhar, Karoly Toth, William S M Wold
Expert Opinion on Biological Therapy|February 6, 2010
Oncolytic (replication-competent) adenoviruses as anticancer agentsKaroly Toth, Debanjan Dhar, William S M Wold
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Advances in Cancer Research|October 2, 2012
Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compoundsWilliam S M Wold, Karoly Toth
Current Gene Therapy|November 28, 2013
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyWilliam S M Wold, Karoly Toth
Virology|September 3, 2003
Adenovirus ADP protein (E3-11.6K), which is required for efficient cell lysis and virus release, interacts with human MAD2BBaoling Ying, William S M Wold
Viruses|October 14, 2011
Increasing the efficacy of oncolytic adenovirus vectorsKaroly Toth, William S M Wold
Expert Opinion on Pharmacotherapy|September 3, 2015
New drug on the horizon for treating adenovirusWilliam S M Wold, Karoly Toth
Virus Research|October 27, 2009
Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosisVera L Tarakanova, William S M Wold
Journal of Virology|August 14, 2003
Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cellsVera L Tarakanova, William S M Wold
Cancer Gene Therapy|September 11, 2004
Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmissionDrew L Lichtenstein, William S M Wold
Methods in Molecular Biology (Clifton, N.J.)|September 28, 2011
Syrian hamster tumor model to study oncolytic Ad5-based vectorsDebanjan Dhar, Karoly Toth, William S M Wold
Expert Opinion on Biological Therapy|February 6, 2010
Oncolytic (replication-competent) adenoviruses as anticancer agentsKaroly Toth, Debanjan Dhar, William S M Wold
Pageof 6